Abstract

Eosinophilic fasciitis is a rare connective tissue disease with unclear etiology and pathogenesis. It is classified as a scleroderma-like syndrome. The disease is characterized by fibrosis of the skin and subcutaneous tissues with significant thickening of fascia. Visceral involvement is rare. Characteristic feature in laboratory tests is peripheral blood eosinophilia. Differential diagnosis should be performed, including ruling out systemic sclerosis, nephrogenic systemic fibrosis, eosinophilia-myalgia syndrome, scleromyxedema, hypereosinophilic syndrome or Churg-Strauss syndrome. Final diagnosis is confirmed by histopathological examination. In treatment of the disease corticosteroids and/or immunosuppressive drugs are used. Some other drugs showed activity in this disease e.g. dapsone, infiximab or rituximab. Prognosis is rather good but sometimes a long-term treatment is necessary. In this paper we summarized the current knowledge on eosinophilic fasciitis.

References

• 1. Antic M., Lautenschlager S., Itin P.H.: Eosinophilic fasciitis 30years after – what do we really know? Report of 11 patients and reviewof the literature. Dermatology, 2006; 213: 93-101 2 Bachmeyer C., Monge M., Dhôte R., Sanguina M., Aractingi S., Mougeot-MartinM.: Eosinophilic fasciitis following idiopathic thrombocytopenicpurpura, autoimmune hemolytic anemia and Hashimoto’sdisease. Dermatology, 1999; 199: 282
  Google Scholar
• 2. in patients with eosinophilic fasciitis. Br. J. Dermatol., 2004;151: 407-412
  Google Scholar
• 3. Bischoff L., Derk C.T.: Eosinophilic fasciitis: demographics, diseasepattern and response to treatment: report of 12 cases and review ofthe literature. Int. J. Dermatol., 2008; 47: 29-35
  Google Scholar
• 4. Bobrowska-Snarska D., Ostanek L., Brzosko M.: Eosinophilic fasciitis-diagnosticand therapeutic difficulties. Ann. Acad. Med. Stetin.,2008; 54: 47-51
  Google Scholar
• 5. Bobrowska-Snarska D., Ostanek L., Brzosko M.: Fasciitis eosinophilica:personal observations and a review of the literature. Pol.Arch. Med. Wewn., 2007; 117: 64-71
  Google Scholar
• 6. Boin F., Hummers L.K.: Scleroderma-like fibrosing disorders.Rheum. Dis. Clin. North Am., 2008; 34: 199-220
  Google Scholar
• 7. Bonnotte B., Chauffert B., Caillot D., Martin F., Lorcerie B.: Successfultreatment with antithymocyte globulin and cyclosporin A ofa severe aplastic anaemia associated with an eosinophilic fasciitis.Br. J. Rheumatol., 1998; 37: 1358-1359
  Google Scholar
• 8. Buchanan R.R., Gordon D.A., Muckle T.J., McKenna F., Kraag G.:The eosinophilic fasciitis syndrome after phenytoin (dilantin) therapy.J. Rheumatol., 1980; 7: 733-736
  Google Scholar
• 9. Bujold J., Boivin C., Amin M., Bouchard J.P., Soucy J.: Eosinophilicfasciitis occurring under treatment with natalizumab for multiplesclerosis. J. Cutan. Med. Surg., 2014; 18: 69-71
  Google Scholar
• 10. Cantini F., Salvarani C., Olivieri I., Padula A., Senesi C., BellandiF., Truglia M.C., Niccoli L., Palchetti R.: Possible association betweeneosinophilic fasciitis and subcutaneous heparin use. J. Rheumatol.,1998; 25: 383-385
  Google Scholar
• 11. Caspi D., Fishel R., Varon M., Yona E., Baratz M., Yaron M.: Multisystempresentation of eosinophilic fasciitis. Rheumatol. Rehabil.,1982; 21: 218-221
  Google Scholar
• 12. Chan V., Soans B., Mathers D.: Ultrasound and magnetic resonanceimaging features in a patient with eosinophilic fasciitis. Australas.Radiol., 2004; 48: 414-417
  Google Scholar
• 13. Cogan E., Roufosse F.: Clinical management of the hypereosinophilicsyndromes. Expert Rev. Hematol., 2012; 5: 275-289
  Google Scholar
• 14. DeGiovanni C., Chard M., Woollons A.: Eosinophilic fasciitis secondaryto treatment with atorvastatin. Clin. Exp. Dermatol., 2006;31: 131-132
  Google Scholar
• 15. de Masson A., Bouaziz J.D., Peffault de Latour R., Benhamou Y.,Moluçon-Chabrot C., Bay J.O., Laquerriere A., Picquenot J.M., MichonneauD., Leguy-Seguin V., Rybojad M., Bonnotte B., Jardin F.,Lévesque H., Bagot M., Socié G..: Severe aplastic anemia associatedwith eosinophilic fasciitis: report of 4 cases and review of the literature.Medicine, 2013; 92: 69-81
  Google Scholar
• 16. Firoz B.F., Goldberg L.H., Landau J., Kaye V., Berman L.: Eosinophilicfasciitis secondary to intravenous iron infusions. Dermatol.Online J., 2010; 16: 5
  Google Scholar
• 17. Gallardo F., Vadillo M., Mitjavila F., Servitje O.: Systemic lupuserythematosus after eosinophilic fasciitis: a case report. J. Am. Acad.Dermatol., 1998; 39: 283-285
  Google Scholar
• 18. Grisanti M.W., Moore T.L., Osborn T.G., Haber P.L.: Eosinophilicfasciitis in children. Semin. Arthritis Rheum., 1989; 19: 151-157
  Google Scholar
• 19. Haddad H., Sundaram S., Magro C., Gergis U.: Eosinophilic fasciitisas a paraneoplastic syndrome, a case report and review of theliterature. Hematol. Oncol. Stem Cell Ther., 2014; 7: 90-92
  Google Scholar
• 20. Hashimoto Y., Takahashi H., Matsuo S., Hirai K., Takemori N.,Nakao M., Miyamoto K., Iizuka H.: Polymerase chain reaction of Borreliaburgdorferi flagellin gene in Shulman syndrome. Dermatology,1996; 192: 136-139
  Google Scholar
• 21. Hayashi N., Igarashi A., Matsuyama T., Harada S.: Eosinophilicfasciitis following exposure to trichloroethylene: successful treatmentwith cyclosporine. Br. J. Dermatol., 2000; 142: 830-832
  Google Scholar
• 22. Herson S., Brechignac S., Piette J.C., Mouthon J.M., CoutellierA., Bletry O., Godeau P.: Capillary microscopy during eosinophilicfasciitis in 15 patients: distinction from systemic scleroderma. Am.J. Med., 1990; 88: 598-600
  Google Scholar
• 23. Janzen L., Jeffery J.R., Gough J., Chalmers I.M.: Response to methotrexatein a patient with idiopathic eosinophilic fasciitis, morphea,IgM hypergammaglobulinemia, and renal involvement. J.Rheumatol., 1995; 22: 1967-1970
  Google Scholar
• 24. Jinnin M., Ihn H., Yamane K., Asano Y., Yazawa N., TamakiK.: Serum levels of tissue inhibitor of metalloproteinase-1 and
  Google Scholar
• 25. Kariyawasam H.H., Robinson D.S.: The eosinophil: the cell andits weapons, the cytokines, its locations. Semin. Respir. Crit. CareMed., 2006; 27: 117-127
  Google Scholar
• 26. Khanna D., Agrawal H., Clements P.J.: Infliximab may be effectivein the treatment of steroid-resistant eosinophilic fasciitis: report ofthree cases. Rheumatology, 2010; 49: 1184-1188
  Google Scholar
• 27. Killen J.W., Swift G.L., White R.J.: Eosinophilic fasciitis with pulmonaryand pleural involvement. Postgrad. Med. J., 2000; 76: 36-37
  Google Scholar
• 28. Kim H.J., Lee S.W., Kim G.J., Lee J.H.: Usefulness of FDG PET/CT in the diagnosis of eosinophilic fasciitis. Clin. Nucl. Med., 2014;39: 801-802
  Google Scholar
• 29. Kim S.W., Rice L., Champlin R., Udden M.M.: Aplastic anemia ineosinophilic fasciitis: responses to immunosuppression and marrowtransplantation. Haematologia, 1997; 28: 131-137
  Google Scholar
• 30. Kirschstein M., Helmchen U., Jensen R., Küster R.M., LehmannH.: Kidney involvement in a 17-year-old boy with eosinophilic fasciitis.Clin. Nephrol., 1999; 52: 183-187
  Google Scholar
• 31. Kissin E.Y., Garg A., Grayson P.C., Dubreuil M., Vradii D., York M.,Simms R.W.: Ultrasound assessment of subcutaneous compressibility:a potential adjunctive diagnostic tool in eosinophilic fasciitis.J. Clin. Rheumatol., 2013; 19: 382-385
  Google Scholar
• 32. Lakhanpal S., Ginsburg W.W., Michet C.J., Doyle J.A., Moore S.B.:Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin. Arthritis Rheum., 1988; 17: 221-231
  Google Scholar
• 33. Lebeaux D., Francès C., Barete S., Wechsler B., Dubourg O., RenouxJ., Maisonobe T., Benveniste O., Gatfossé M., Bourgeois P., AmouraZ., Cacoub P., Piette J.C., Sène D.: Eosinophilic fasciitis (Shulman disease):new insights into the therapeutic management from a seriesof 34 patients. Rheumatology, 2012; 51: 557-561
  Google Scholar
• 34. Lebeaux D., Sène D.: Eosinophilic fasciitis (Shulman disease).Best. Pract. Res. Clin. Rheumatol., 2012; 26: 449-458
  Google Scholar
• 35. Liou C.H., Huang G.S., Taylor J.A., Juan C.J., Gao H.W., Chen C.Y.:Eosinophilic fasciitis in a military recruit: MRI evaluation with clinicalcorrelation. Skeletal Radiol., 2003; 32: 52-57
  Google Scholar
• 36. Mallepalli J.R., Quinet R.J., Sus R.: Eosinophilic fasciitis inducedby fire ant bites. Ochsner. J., 2008; 8: 114-118
  Google Scholar
• 37. Małdyk H., Jędryka-Góral A., Połowiec Z.: Fasciitis eosinophilicain the light of observed cases. Reumatologia, 1983; 21: 277–284
  Google Scholar
• 38. Martin R.W., Duffy J., Lie J.T.: Eosinophilic fasciitis associatedwith use of L-tryptophan: a case-control study and comparisonof clinical and histopathologic features. Mayo Clin. Proc., 1991;66: 892-898
  Google Scholar
• 39. Moriguchi M., Terai C., Kuroki S., Tanaka E., Someya N., TsunodaY., Kashiwazaki S.: Eosinophilic fasciitis complicated with peripheralpolyneuropathy. Intern. Med., 1998; 37: 417-420
  Google Scholar
• 40. Pomann J.J., Rudner E.J.: Scleromyxedema revisited. Int. J. Dermatol.,2003; 42: 31-35
  Google Scholar
• 41. Puszczewicz M., Zimmermann-Górska I., Pietrzak-KaczmarekH., Łazowski S.: Diagnostic problems in eosinophilic fasciitis. Pol.Arch. Med. Wewn., 2006; 116: 777-780
  Google Scholar
• 42. Rieber N., Belohradsky B.H.: AHR activation by tryptophan-pathogenichallmark of Th17-mediated inflammation in eosinophilicfasciitis, eosinophilia-myalgia-syndrome and toxic oil syndrome?Immunol. Lett., 2010; 128: 154-155
  Google Scholar
• 43. Ristic B., Zecevic R.D., Karadaglic D.: Treatment of eosinophilicfasciitis with cimetidine. Vojnosanit. Pregl., 2001; 58: 437-440
  Google Scholar
• 44. Rizzo S.: Eosinophilic pleuropericarditis and fasciitis. A newcase. Monaldi. Arch. Chest Dis., 2002; 57: 311-313
  Google Scholar
• 45. Romano C., Rubegni P., De Aloe G., Stanghellini E., D›AscenzoG., Andreassi L., Fimiani M.: Extracorporeal photochemotherapy inthe treatment of eosinophilic fasciitis. J. Eur. Acad. Dermatol. Venereol.,2003; 17: 10-13
  Google Scholar
• 46. Ronneberger M., Janka R., Schett G., Manger B.: Can MRI substitutefor biopsy in eosinophilic fasciitis? Ann. Rheum. Dis., 2009;68: 1651-1652
  Google Scholar
• 47. Rota E., Nallino M.G., Bainotti S., Formica M.: Nephrogenic systemicfibrosis: an unusual scleroderma-like fibrosing disorder. Rheumatol.Int., 2010; 30: 1389-1391
  Google Scholar
• 48. Scheinberg M., Hamerschlak N., Kutner J.M., Ribeiro A.A., FerreiraE., Goldenberg J., Kiss M.H., Chahade W.H.: Rituximab in refractoryautoimmune diseases: Brazilian experience with 29 patients(2002-2004). Clin. Exp. Rheumatol., 2006; 24: 65-69
  Google Scholar
• 49. Scott D.G., Watts R.A.: Epidemiology and clinical features of systemicvasculitis. Clin. Exp. Nephrol., 2013; 17: 607-610
  Google Scholar
• 50. Serrano-Grau P., Mascaró-Galy J.M., Iranzo P.: Eosinophilic fasciitisafter taking simvastatin. Actas Dermosifiliogr., 2008; 99: 420-421
  Google Scholar
• 51. Shulman L.E.: Diffuse fasciitis with eosinophilia: a new syndrome?Trans. Assoc. Am. Physicians., 1975; 88: 70-86
  Google Scholar
• 52. Silló P., Pintér D., Ostorházi E., Mazán M., Wikonkál N., Pónyai K.,Volokhov D.V., Chizhikov V.E., Szathmary S., Stipkovits L., Kárpáti S.:Eosinophilic fasciitis associated with Mycoplasma arginini infection.J. Clin. Microbiol., 2012; 50: 1113-1117
  Google Scholar
• 53. Silny W., Osmola-Mańkowska A., Czarnecka-Operacz M., Żaba R.,Dańczak-Pazdrowska A., Marciniak A.: Eosinophilic fascitis: a reportof two cases treated with ultraviolet A1 phototherapy. Photodermatol.Photoimmunol. Photomed., 2009; 25: 325-327
  Google Scholar
• 54. Smiley A.M., Husain M., Indenbaum S.: Eosinophilic fasciitis inassociation with thyroid disease: a report of three cases. J. Rheumatol.,1980; 7: 871-876
  Google Scholar
• 55. Smith L.C., Cox N.H.: Dapsone treatment for eosinophilic fasciitis.Arch. Dermatol., 2008; 144: 845-847
  Google Scholar
• 56. Sugiura K., Matsumoto T., Muro Y., Akiyama M.: Unilaterallydominant eosinophilic fasciitis after influenza vaccination. J. Am.Acad. Dermatol., 2013; 69: e269-270
  Google Scholar
• 57. Suresh E., Doherty V., Schofield O., Goddard C., Dhillon V.: Eosinophilicfasciitis and eosinophilic colitis: a rare association. Rheumatology,2005; 44: 411-413
  Google Scholar
• 58. Swygert L.A., Maes E.F., Sewell L.E., Miller L., Falk H., KilbourneE.M.: Eosinophilia-myalgia syndrome. Results of national surveillance.JAMA, 1990; 264: 1698-1703
  Google Scholar
• 59. Tyndall A., Fistarol S.: The differential diagnosis of systemicsclerosis. Curr. Opin. Rheumatol., 2013; 25: 692-699
  Google Scholar
• 60. Varga J., Kähäri V.M.: Eosinophilia-myalgia syndrome, eosinophilicfasciitis, and related fibrosing disorders. Curr. Opin. Rheumatol.,1997; 9: 562-570
  Google Scholar
• 61. Watts R.A., Merry P.: Familial eosinophilic fasciitis and breastcancer. Br. J. Rheumatol., 1994; 33: 93-94
  Google Scholar
• 62. Wojas-Pelc A., Wielowieyska-Szybińska D., Lipko-GodlewskaS.: Eosinophilic fasciitis current knowledge. Pol. Merkuriusz Lek.,2004; 96: 585-588
  Google Scholar

Full text